Iqymune

Human normal immunoglobulin, the active ingredient in Iqymune, is an immunoglobulin preparation presented as a sterile solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is indicated for patients with primary or secondary immunodeficiency disorders who lack sufficient endogenous immunoglobulins.

GNH USA supplies Iqymune as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide. The product conforms to EU standards and is manufactured under strict quality controls.

Iqymune is used to replace deficient IgG antibodies in disorders of the immune system. - Primary immunodeficiency diseases: replacement of IgG reduces infection frequency and severity. - Secondary immunodeficiency (e.g., chemotherapy‑induced): supplementation of IgG supports immune function during treatment. - Post‑bone marrow transplant hypogammaglobulinemia: provides passive immunity while the graft engrafts.

Administration of Iqymune may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring during or after infusion. - Fever: transient rise in body temperature, usually self‑limiting. - Chills: shaking sensations commonly reported with the start of infusion. - Nausea: mild gastrointestinal discomfort during administration. - Fatigue: feeling of tiredness that may persist for several hours. - Infusion‑related reactions: erythema, itching, or mild hypotension during the infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical intervention. - Thromboembolic events: blood clots that can lead to vascular complications. - Acute renal failure: sudden loss of kidney function, particularly with high‑volume infusions. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia. - Severe hemolytic transfusion reaction: rare but potentially life‑threatening.

Before initiating Iqymune therapy, clinicians should consider several safety measures to minimize risks. - Screen for IgA deficiency: patients with anti‑IgA antibodies may develop severe anaphylactic reactions. - Monitor renal function: high‑volume infusions can place stress on the kidneys. - Assess thrombotic risk: evaluate history of clotting disorders before treatment. - Observe for infusion reactions: start infusion at a slow rate and increase gradually. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use may reduce vaccine efficacy and increase infection risk. - IgA‑deficient plasma products: may trigger severe anaphylaxis in sensitized patients.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding due to increased plasma volume. - Diuretics: adjust dosing to maintain fluid balance during infusion. - Inactivated vaccines: immune response may be diminished, requiring timing considerations.